Vir Biotechnology Decreases The Surplus Population

The beleaguered group is to cut its headcount and refocus on its hepatitis programs.  

Monster Ztudio/Shutterstock.com

Spare a thought for the 12% of Vir Biotechnology, Inc. employees who will be having a pretty unfestive festive season. The antiviral specialist is to make 75 positions redundant as part of a cost-cutting drive that will also see it refocus development efforts yet again and close two R&D facilities.

Key Takeaways

  • Vir has had a hard year and is cutting staff and closing sites, refocusing on potentially high-growth areas

Vir hopes to save at least $40m per year as a result. The fact that its coffers were already swollen...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.